PDL BioPharma Story Overview

PDLI -- USA Stock  

USD 2.55  0.02  0.79%

Macroaxis does not monitor all media channels or aggregates social signals for PDL BioPharma. But even though we do not provide professional-grade financial sentiment analysis on PDL BioPharma, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for PDL BioPharma. Additionally take a look at PDL BioPharma Hype Analysis, PDL BioPharma Correlation and PDL BioPharma Performance.
Taking Tally Of The New York Times Company , PDL BioPharma, Inc.
The shares of The New York Times Company have increased by more than 33.46 percent this year alone. The shares recently went down by -4.83 percent or -0.9 and now trades at 17.75. The Dirty Secret to Trading PDL BioPharma, Inc. , The New York Times ... - USA Commerce Daily

Read More...   

Story Momentum

This media report from stocknewsgazette.com distributed on December 8, 2017 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 1.75% . The trading delta at closing time when the story was published against the current closing price is 10.88% .

Similar stores for PDL BioPharma

a day ago at www.macroaxis.com 
Exercise or conversion by Torres Laurie C of 2188 shares of PDL BioPharma subject to Rule 16b-3
Macroaxis News
Filed transaction by Pdl Biopharma Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
few days ago at http://stocknewsgazette.com 
Taking Tally Of CRISPR Therapeutics AG , PDL BioPharma, Inc.
news
StockNewsGazetteFull coverage
over a week ago at http://stockmarketfloor.com 
PDL BioPharma, Inc. move of 0.38 percent on Friday and 3-months average volume stands at 1308.02shares
news
Stock Market Floor Full coverage
over two weeks ago at http://cardinalweekly.com 
PDL Biopharma Inc Move as Institutional Investors Sentiment Falls
news
The Cardinal Weekly Full coverage
over two weeks ago at http://cardinalweekly.com 
Pdl Biopharma Inc Could Improve Your Long Portfolio After Less Shorts Reported
news
The Cardinal Weekly Full coverage
over two weeks ago at http://www.mareainformativa.com 
Analysts Anticipate PDL BioPharma Inc Will Announce Earnings of 0.07 Per Share
news
Marea Informative Full coverage
over three weeks ago at http://nasdaqclick.com 
PDL BioPharma, Inc. Targeted Mover
nasdaq News
Nasdaq Click Full coverage
over a month ago at www.macroaxis.com 
Sale by Torres Laurie C of 2187 shares of PDL BioPharma
Macroaxis News
Filed transaction by Pdl Biopharma Inc officer. General open market or private sale of non-derivative or derivative security
over a month ago at www.macroaxis.com 
Sale by Klein Joseph Iii of 400 shares of PDL BioPharma
Macroaxis News
Filed transaction by Pdl Biopharma Inc director. General open market or private sale of non-derivative or derivative security
over a month ago at http://www.thecoinguild.com 
Shares Watch Investors Taking a Second Look at PDL BioPharma, Inc. After Recent Market Moves
news
The Coin GuildFull coverage
over a month ago at http://stocknewsgazette.com 
Which of 2 stocks would appeal to long-term investors Sally Beauty Holdings, Inc. , PDL BioPharma, Inc.
news
StockNewsGazetteFull coverage
over three months ago at http://www.nasdaqfortune.com 
PDL BioPharma, Inc. receives consensus rating of 3.00
nasdaq News
Nasdaq Fortune Full coverage
over three months ago at www.macroaxis.com 
Sale by Torres Laurie C of 600 shares of PDL BioPharma
Macroaxis News
Filed transaction by Pdl Biopharma Inc officer. General open market or private sale of non-derivative or derivative security

Z Score

Z Score Comparative Analysis

  Z Score 
      PDL BioPharma Comparables 
PDL BioPharma is currently under evaluation in z score category among related companies. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in late 1960s at New York University..

Peers

PDL BioPharma Related Equities

DOVA  9.06 %   
0%
100.0%
DMPI  7.76 %   
0%
85.0%
EARS  7.25 %   
0%
79.0%
DVAX  5.97 %   
0%
65.0%
ECYT  4.66 %   
0%
51.0%
DRNA  1.75 %   
0%
19.0%
NK  1.45 %   
0%
16.0%
CO  3.46 %   
38.0%
0%
Additionally take a look at PDL BioPharma Hype Analysis, PDL BioPharma Correlation and PDL BioPharma Performance. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Search macroaxis.com